Aveo stock plunges after delay in FDA approval submission for cancer drug

Aveo stock plunges after delay in FDA approval submission for cancer drug

Submitted by admin on February 1, 2019 - 12:16am
Source: 
Bizjournals
News Tags: 
Aveo Oncology
kidney cancer
FDA
tivozanib
advanced renal cell carcinoma
Headline: 
Aveo stock plunges after delay in FDA approval submission for cancer drug
snippet: 

Shares of Cambridge biotech Aveo Oncology fell by more than half on Thursday after it announced it had once again received pushback from the FDA over its kidney cancer drug.

Do Not Allow Advertisers to Use My Personal information